Aging is not a single process. The updated hallmarks framework identifies twelve interconnected mechanisms that drive biological decline: genomic instability, telomere attrition, epigenetic alterations, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, chronic inflammation, and others. No single intervention addresses all of them. That reality has driven interest in anti-aging peptides, short-chain amino acid sequences that target specific hallmarks with a degree of precision that small-molecule drugs often lack.
This guide examines the six most evidence-backed peptide classes for longevity applications, ranked by strength of clinical data, mechanism clarity, and relevance to age-related decline. Every compound here has published peer-reviewed research; none has FDA approval for anti-aging itself.
The Science of Aging and Peptide Interventions
The hallmarks of aging, first codified by Lopez-Otin et al. in 2013 and expanded in 2023, provide a useful framework for understanding where peptides fit into longevity science. Several hallmarks are directly addressable by peptide-based interventions:
Mitochondrial dysfunction accelerates with age as the electron transport chain loses efficiency, reactive oxygen species accumulate, and ATP production declines. This manifests as reduced exercise tolerance, cardiac dysfunction, and neurodegeneration. SS-31 targets this hallmark directly.
Telomere attrition sets an upper limit on replicative capacity. As telomeres shorten below critical thresholds, cells enter senescence or apoptosis. Epithalon acts on this pathway through telomerase activation.
Altered intercellular communication encompasses chronic low-grade inflammation ("inflammaging") and immune senescence. Thymosin alpha 1 and BPC-157 modulate these processes through distinct mechanisms.
Deregulated nutrient sensing includes the somatotropic axis. Growth hormone secretion declines approximately 14% per decade after age 30, contributing to sarcopenia, visceral fat accumulation, and reduced bone density. Sermorelin addresses this axis.
Epigenetic alterations and loss of proteostasis affect every tissue. GHK-Cu influences gene expression broadly, with effects on collagen synthesis, antioxidant enzymes, and DNA repair genes.
Disabled macroautophagy is another recognized hallmark, and a notable gap in the current peptide toolkit. Autophagy — the cell's process of breaking down damaged organelles, misfolded proteins, and dysfunctional components — declines with age, allowing cellular debris to accumulate in long-lived tissues like cardiac muscle and neurons. While non-peptide compounds (spermidine, rapamycin) have shown autophagy-promoting effects in model organisms, no peptide in the biohacking space directly targets this pathway. Some researchers hypothesize that mitochondrial-targeted peptides like SS-31 may indirectly support autophagy by improving cellular energy availability, but this remains speculative.
No peptide addresses all twelve hallmarks. The practical approach is targeting the hallmarks most relevant to an individual's aging phenotype, guided by biomarker data.
1. SS-31 (Elamipretide), Best for Mitochondrial Health
SS-31 is a cell-permeable tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that concentrates 1,000 to 5,000-fold in the inner mitochondrial membrane, where it binds cardiolipin to stabilize cristae structure and optimize electron transport chain efficiency.Mechanism. SS-31 reduces electron leak at complexes I and III, lowers mitochondrial reactive oxygen species production, and improves ADP sensitivity through the adenine nucleotide translocator. Unlike conventional antioxidants that scavenge free radicals after formation, SS-31 prevents their generation at the source.
Clinical evidence. Elamipretide received FDA accelerated approval in 2025 for improving muscle strength in patients with Barth syndrome, a rare mitochondrial cardiomyopathy. Phase II/III trials are ongoing or completed for primary mitochondrial myopathy (MMPOWER-3), heart failure with reduced ejection fraction (PROGRESS-HF), and age-related macular degeneration (ReCLAIM). In aged mice, SS-31 treatment reversed age-related redox stress and improved exercise tolerance without increasing mitochondrial content, suggesting improved efficiency of existing mitochondria rather than biogenesis.
Relevance to aging. Mitochondrial dysfunction is arguably the most consequential hallmark for functional decline. Age-related drops in skeletal muscle mitochondrial function correlate directly with frailty, falls, and loss of independence. SS-31 has the strongest translational evidence of any peptide in this guide.
Limitations. FDA approval is for Barth syndrome only. Off-label use for general anti-aging remains unsupported by completed Phase III data in healthy older adults. The peptide requires subcutaneous injection and is not orally bioavailable.
2. Epithalon, Best for Telomere Support
Epithalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide based on epithalamin, a pineal gland extract studied extensively by Russian gerontologist Vladimir Khavinson beginning in the 1980s.
Mechanism. Epithalon activates telomerase by upregulating expression of hTERT, the catalytic subunit of the enzyme. In human fetal fibroblasts and neonatal dermal fibroblasts, epithalon treatment induced telomerase activity and elongated telomeres beyond untreated controls. A 2025 study published in Biogerontology confirmed these findings and identified an additional mechanism: epithalon may also activate the alternative lengthening of telomeres (ALT) pathway in certain cell types, while paradoxically downregulating telomerase in cancer cell lines.
Preclinical evidence. In animal models, chronic epithalon administration extended maximum lifespan in several rodent strains. Khavinson's group reported reactivation of telomerase in human somatic cells and restoration of melatonin secretion patterns in aged primates. However, these studies originate predominantly from a single research group, and independent replication from Western laboratories has been limited until the 2025 Biogerontology publication.
Relevance to aging. Telomere length is an established biomarker of biological age, and critically short telomeres trigger cellular senescence. Telomerase activation represents a mechanistically direct approach to this hallmark. However, indiscriminate telomerase activation raises theoretical oncology concerns, since most cancers reactivate telomerase to achieve replicative immortality.
Limitations. No human clinical trials meeting Western regulatory standards have been completed. The dual effect on normal versus cancer cells observed in vitro is reassuring but unvalidated in vivo. Epithalon is not approved in any jurisdiction and is available only as a research chemical.
3. GHK-Cu, Best for Skin Aging and Collagen
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide-copper chelate found in human plasma, saliva, and urine. Plasma concentrations decline from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60.
Mechanism. GHK-Cu activates or suppresses expression of over 4,000 human genes at a threshold of ≥50% mRNA expression change. A broader analysis from the same in vitro Connectivity Map dataset, including any level of change, identified effects on approximately 7,800 genes (~31% of the genome). These two figures reflect different thresholds from the same dataset and should not be conflated as equivalent. Upregulated pathways include collagen synthesis, elastin production, glycosaminoglycan assembly, antioxidant enzyme expression (superoxide dismutase, glutathione), and DNA repair genes. It also stimulates angiogenesis, nerve outgrowth, and dermal fibroblast proliferation.
Clinical evidence. In a 12-week controlled trial using thigh skin biopsies (not facial application), GHK-Cu applied topically improved collagen production in 70% of women treated, compared to 50% with vitamin C and 40% with retinoic acid. These results may not directly translate to facial skincare use. A separate double-blind, split-face study of 60 participants aged 40 to 65 demonstrated a 22% increase in skin firmness and a 16% reduction in fine lines over 12 weeks with 0.05% GHK-Cu serum versus placebo. A 2025 clinical trial of 21 women showed a 28% average increase in collagen density after 3 months of daily application, with top responders reaching 51%.
Relevance to aging. Skin is the most visible organ of aging, and collagen loss (approximately 1% per year after age 30) drives wrinkle formation, thinning, and impaired wound healing. GHK-Cu addresses this through multiple convergent pathways rather than a single mechanism, which may explain its broad efficacy across skin endpoints.
Limitations. Topical penetration limits systemic effects. Clinical improvements in the 15% to 25% range, while statistically significant, remain smaller than those achieved with prescription retinoids or energy-based devices. Injectable GHK-Cu for systemic anti-aging effects lacks clinical trial support.
4. Thymosin Alpha 1, Best for Immune Aging
Thymosin alpha 1 (Ta1) is a 28-amino-acid peptide originally isolated from thymic tissue. It is approved as a prescription drug (Zadaxin) in over 35 countries for hepatitis B/C and as a vaccine adjuvant, though not in the United States.
Mechanism. Ta1 stimulates differentiation of T-cell precursors, enhances dendritic cell maturation, modulates Toll-like receptor signaling, and shifts immune responses from Th2 toward Th1 predominance. In aging, thymic involution progressively reduces naive T-cell output, leading to a contracted T-cell repertoire, impaired vaccine responses, and increased susceptibility to infections and malignancy.
Clinical evidence. Randomized trials in elderly subjects demonstrated that Ta1 administered as an adjunct to influenza vaccination significantly increased seroconversion rates compared to vaccine alone. During the COVID-19 pandemic, Ta1 reduced cytokine storm severity, reversed T-cell exhaustion markers, and improved lymphocyte counts in critically ill patients across multiple observational studies. A 2025 review in the International Journal of Molecular Sciences documented that Ta1 use in patients over 55 was associated with radiographic signs of thymus reactivation on PET-CT imaging, accompanied by measurable T-lymphocyte activation.
Relevance to aging. Immune senescence is a primary driver of age-related morbidity and mortality. Impaired immune surveillance contributes to cancer, chronic infections, and reduced vaccine efficacy. Ta1 addresses the root cause (thymic decline) rather than downstream symptoms.
Limitations. Clinical trials have focused on specific disease states rather than healthy aging. Whether Ta1 meaningfully extends healthspan in immunocompetent older adults remains unproven. Cost is substantial, and US access requires compounding pharmacy sourcing.
5. Sermorelin, Best for Age-Related GH Decline
Sermorelin (GHRH 1-29) is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone. It was FDA-approved for pediatric GH deficiency in 1997 but voluntarily withdrawn from the market by its manufacturer in 2008 for commercial reasons.
Mechanism. Sermorelin binds GHRH receptors on anterior pituitary somatotrophs, stimulating synthesis and pulsatile release of endogenous growth hormone. Unlike exogenous GH, sermorelin preserves negative feedback loops, maintains physiological secretion patterns, and does not suppress endogenous production.
Clinical evidence. A clinical trial of GHRH analog administration in age-advanced men and women found significant increases in 12-hour integrated nocturnal GH levels in both sexes. Men experienced increases in lean body mass, insulin sensitivity, and general well-being. Skin thickness increased in both genders. Sermorelin has a well-characterized safety profile from its years as an FDA-approved drug, with injection-site reactions and transient flushing as the most commonly reported adverse effects.
Relevance to aging. GH secretion declines approximately 14% per decade beginning in the third decade of life, a phenomenon termed somatopause. This decline contributes to sarcopenia, increased adiposity, reduced bone mineral density, impaired sleep architecture, and cognitive slowing. Restoring GH pulsatility through GHRH stimulation, rather than replacing GH exogenously, represents a physiologically conservative intervention strategy.
Limitations. The original FDA-approved formulation is no longer commercially manufactured. Current access is through compounding pharmacies, which introduces quality variability. Long-term efficacy and safety data for anti-aging use in healthy adults are limited. Cycling is recommended to avoid pituitary desensitization, typically 5 days on and 2 days off or 8 to 12 weeks on followed by 4 to 8 weeks off.
6. Selank and Semax, Best for Cognitive Aging
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) and Semax (Met-Glu-His-Phe-Pro-Gly-Pro) are synthetic peptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Both are approved for clinical use in Russia: Semax for stroke recovery and cognitive disorders since 1994, and Selank for anxiety and neurasthenia.
Mechanisms. Semax is a synthetic analog of ACTH(4-7) that lacks hormonal activity but demonstrates potent neurotrophic effects. It increases brain-derived neurotrophic factor (BDNF) protein levels approximately 1.4-fold in the rat hippocampus, modulates serotonergic and dopaminergic neurotransmission, and has demonstrated neuroprotective effects in ischemic brain injury models. Selank is based on the endogenous immunomodulatory peptide tuftsin, extended with a Pro-Gly-Pro sequence for metabolic stability. It enhances GABAergic transmission, reduces anxiety-like behavior in animal models, stabilizes enkephalin degradation, and improves memory consolidation under stress conditions.
Preclinical and clinical evidence. Semax has been studied in over 100,000 patients in Russia for stroke rehabilitation, where it improved cognitive recovery and reduced neurological deficit scores. A 2024 study demonstrated that coadministration of Semax with a related analog produced additive effects on BDNF expression. Selank has demonstrated anxiolytic effects comparable to benzodiazepines without sedation, motor impairment, or dependence in Russian clinical studies.
Relevance to aging. Cognitive decline is among the most feared consequences of aging. BDNF levels decrease with age and correlate with hippocampal volume loss and memory impairment. Neuroinflammation, which Selank modulates through GABAergic and immune pathways, accelerates neurodegeneration. Both peptides address upstream drivers of cognitive aging rather than masking symptoms.
Limitations. The overwhelming majority of clinical data originates from Russian and CIS-country studies, with limited independent Western validation. Long-term safety data beyond several months is scarce. Neither peptide is approved outside of Russia and several former Soviet states. Intranasal administration, while convenient, introduces bioavailability variability.
Anti-Aging Peptide Stacking Strategies
Because each peptide targets a different hallmark, combining compounds that address complementary mechanisms is a logical strategy. No clinical trials have validated anti-aging peptide stacks, but several combinations have theoretical coherence:
Mitochondrial plus telomere support. SS-31 paired with epithalon targets two independent hallmarks (mitochondrial dysfunction and telomere attrition) with no known mechanistic overlap or interaction. See the Epithalon vs SS-31 comparison for a side-by-side analysis.
GH restoration plus tissue repair. Sermorelin combined with BPC-157 addresses somatopause while supporting connective tissue integrity. BPC-157 may enhance GH receptor expression in tendon cells, potentially creating a synergistic interaction with sermorelin-stimulated GH release.
Immune plus cognitive. Thymosin alpha 1 paired with Selank or Semax addresses immune senescence and neuroinflammation simultaneously. The Selank vs Semax comparison explains how to choose between these two cognitive peptides. Both pathways converge on chronic inflammatory signaling, which suggests potential additive benefit.
Conservative starting approach. Begin with a single peptide targeting your most relevant hallmark (identified through biomarker testing). Establish baseline response over 8 to 12 weeks before considering additions. Monitor biomarkers at each stage to attribute effects to specific compounds.
Monitoring and Biomarkers of Aging
Effective peptide-based anti-aging strategies require objective measurement. Key biomarker categories include:
Hormonal panels. IGF-1, growth hormone stimulation tests, DHEA-S, and thyroid function establish somatotropic axis status and track sermorelin response.
Inflammatory markers. High-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor alpha, and lymphocyte subset panels track immune aging and thymosin alpha 1 response.
Mitochondrial function. Cardiopulmonary exercise testing (VO2 max), lactate threshold, and CoQ10 levels provide functional mitochondrial assessments relevant to SS-31 use.
Telomere length. Quantitative PCR-based or Flow-FISH telomere length assays establish baseline and track epithalon response, though measurement variability between laboratories is substantial.
Epigenetic clocks. Second-generation clocks such as GrimAge and DunedinPACE measure biological aging rate rather than static age, providing composite assessments that may capture multi-system peptide effects more sensitively than single-hallmark biomarkers.
Skin-specific endpoints. Cutometry (elasticity), high-frequency ultrasound (dermal density), and standardized photography track GHK-Cu responses with greater objectivity than visual assessment alone.
Testing at baseline, 12 weeks, and 24 weeks provides minimum useful data points. Annual comprehensive panels support long-term protocol optimization.
Legal Status and Access
Regulatory status varies significantly across the peptides in this guide:
FDA-approved (for specific indications). Elamipretide is approved for Barth syndrome. Sermorelin was previously approved for pediatric GH deficiency but is no longer commercially manufactured; it remains available through compounding pharmacies with a prescription.
Approved outside the US. Thymosin alpha 1 (Zadaxin) is approved in over 35 countries. Semax and Selank are approved in Russia.
Research chemical status. Epithalon, GHK-Cu (injectable form), and BPC-157 are available primarily as research chemicals. BPC-157 was classified as a Category 2 bulk drug substance by the FDA in 2023, restricting commercial compounding. BPC-157 is prohibited by the World Anti-Doping Agency.
Compounding access. In the United States, sermorelin, thymosin alpha 1, and SS-31 may be available through 503A or 503B compounding pharmacies with a valid prescription, subject to evolving FDA enforcement. See the peptide legality guide for the current regulatory landscape.
Working with a licensed physician experienced in peptide therapy is essential for legal access, appropriate dosing, and safety monitoring.
Conclusion
Anti-aging peptides represent a mechanistically diverse toolkit for addressing specific hallmarks of biological aging. SS-31 leads in clinical validation with FDA approval for a mitochondrial disease and multiple ongoing Phase III trials. GHK-Cu has the strongest topical evidence for skin aging. Thymosin alpha 1 has the broadest international regulatory acceptance. Epithalon, Selank, and Semax have compelling preclinical data but lack Western clinical validation. Sermorelin offers the most physiologically conservative approach to GH restoration.
The field is advancing rapidly. The 2025 FDA approval of elamipretide marks the first mitochondrial peptide therapeutic to reach market, and ongoing trials across multiple age-related conditions suggest the pipeline will continue to expand. For individuals exploring peptide-based longevity strategies, the priorities remain the same: select compounds based on biomarker-identified deficits, start conservatively, monitor objectively, and work with qualified medical supervision.